secwatch.observer — SEC 8-K summary
======================================

Issuer:     InfuSystem Holdings, Inc (INFU)
CIK:        0001337013
Form:       8-K
Filed at:   2024-09-12T23:59:59+00:00
Accession:  0001628280-24-040251
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InfuSystem releases updated 2024 outlook: revenue ~$134.2M, Adj. EBITDA ~$26.5M
-------------------------------------------------------------------------------

- 2024 estimated net revenue of $134.2M (+6.7% YoY); Adj. EBITDA $26.5M (high-teens margin).
- Recent distribution agreements: Smith+Nephew RENASYS EDGE NPWT system; exclusive U.S. ChemoMouthpiece with Sanara MedTech.
- Patient Services revenue $77.3M (TTM 6/30/24); Device Solutions $52.1M; gross margins 64.9% and 29.4%.
- Net leverage 1.53x; $40.5M total liquidity; $20M share repurchase program authorized.
- Five consecutive years of record revenue; 12% revenue CAGR 2019-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1337013/000162828024040251/0001628280-24-040251-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1337013/000162828024040251/infu-20240912.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-040251

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer